ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2022
Therapeutic Approaches to the Neurologic Manifestations of COVID-19.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Use of Mobile Technologies for Smoking Cessation Among Smokers and Former Smokers: Systematic Review.Journal of medical Internet research · 2026Pooled it
- Long COVID brain fog treatment: An early-phase randomized controlled trial of constraint-induced cognitive therapy signals go.Rehabilitation psychology · 2026Trial
- Evaluation of a multidisciplinary neurological rehabilitation program for the post-COVID-19 condition.Journal of neurology · 2026Article
- Immunomodulatory Mechanisms Underlying Neurological Manifestations in Long COVID: Implications for Immune-Mediated Neurodegeneration.International journal of molecular sciences · 2025Review
- Neuropsychiatric Manifestations of Long COVID-19: A Narrative Review of Clinical Aspects and Therapeutic Approaches.Life (Basel, Switzerland) · 2025Review
- Impact of healthcare system strain on the implementation of ICU sedation practices and encephalopathy burden during the early COVID-19 pandemic.GeroScience · 2025Article
- Neuropsychiatric manifestations of Long COVID in India: a persistent problem 2.5 years after disease onset.Frontiers in neurology · 2025Article
- Review
- COVID-19 and the brain: understanding the pathogenesis and consequences of neurological damage.Molecular biology reports · 2024Review
- COVID-19-associated encephalopathy: connection between neuroinflammation and microbiota-gut-brain axis.Frontiers in microbiology · 2024Review
- Cognitive functioning in patients with neuro-PASC: the role of fatigue, mood, and hospitalization status.Frontiers in neurology · 2024Article
- Addressing Long COVID Sequelae and Neurocovid: Neuropsychological Scenarios and Neuroimaging Findings.Advances in experimental medicine and biology · 2024Review
- Headache in COVID-19 and Long COVID: to Know Facts for Clinical Practice.Current neurology and neuroscience reports · 2023Review
- Article
- Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity.Annals of neurology · 2023Article
- Thrombectomy of an Acute Ischemic Stroke in a Child with COVID-19 and MIS-C: Case Analysis and Literature Context.Children (Basel, Switzerland) · 2023Article
- Household income is associated with functional outcomes in a multi-institutional cohort of patients with ischemic stroke and COVID-19.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2023Article
- Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics.Cells · 2023Review
- Cortical Grey matter volume depletion links to neurological sequelae in post COVID-19 "long haulers".BMC neurology · 2023Article
- SARS-CoV-2 omicron BA.5 and XBB variants have increased neurotropic potential over BA.1 in K18-hACE2 mice and human brain organoids.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As of May 2022, there have been more than 527 million infections with severe acute respiratory disease coronavirus type 2 (SARS-CoV-2) and over 6.2 million deaths from Coronavirus Disease 2019 (COVID-19) worldwide. COVID-19 is a multisystem illness with important neurologic consequences that impact long-term morbidity and mortality. In the acutely ill, the neurologic manifestations of COVID-19 can include distressing but relatively benign symptoms such as headache, myalgias, and anosmia; however, entities such as encephalopathy, stroke, seizures, encephalitis, and Guillain-Barre Syndrome can cause neurologic injury and resulting disability that persists long after the acute pulmonary illness. Furthermore, as many as one-third of patients may experience persistent neurologic symptoms as part of a Post-Acute Sequelae of SARS-CoV-2 infection (Neuro-PASC) syndrome. This Neuro-PASC syndrome can affect patients who required hospitalization for COVID-19 or patients who did not require hospitalization and who may have had minor or no pulmonary symptoms. Given the large number of individuals affected and the ability of neurologic complications to impair quality of life and productivity, the neurologic manifestations of COVID-19 are likely to have major and long-lasting personal, public health, and economic consequences. While knowledge of disease mechanisms and therapies acquired prior to the pandemic can inform us on how to manage patients with the neurologic manifestations of COVID-19, there is a critical need for improved understanding of specific COVID-19 disease mechanisms and development of therapies that target the neurologic morbidities of COVID-19. This current perspective reviews evidence for proposed disease mechanisms as they inform the neurologic management of COVID-19 in adult patients while also identifying areas in need of further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.